Pharmacotherapy for diabetic retinopathy

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1123-1131

  Schwartz, Stephen G ^a   Flynn Jr , Harry W ^a   Scott, Ingrid U ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetic macular edema; Nonproliferative diabetic retinopathy; Proliferative diabetic retinopathy; Randomized clinical trial; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BEVASIRANIB; DEXAMETHASONE; ETANERCEPT; FENOFIBRATE; FLUOCINOLONE ACETONIDE; HYALURONIDASE; ILUVIEN; INFLIXIMAB; MICROPLASMIN; NEPAFENAC; OCTREOTIDE; PEGAPTANIB; PLASMIN; RANIBIZUMAB; RAPAMYCIN; ROSIGLITAZONE; RUBOXISTAURIN; TRAP EYE; TRIAMCINOLONE ACETONIDE; TRIESENCE; TRIVARIS; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; EYE DROPS;

BREAST CANCER; CATARACT; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ENDOPHTHALMITIS; HUMAN; IMPLANT; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; DRUG ADMINISTRATION ROUTE;

DIABETIC RETINOPATHY; DRUG ADMINISTRATION ROUTES; HUMANS; OPHTHALMIC SOLUTIONS;

EID: 67649512882     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902910092     Document Type: Review

References (98)

1. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485 (Pubitemid 38456282)
2. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986 (Pubitemid 23307905)
3. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998;352:837-853 (Pubitemid 28416718)
4. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009;5:3-7
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806
6. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88:583-600
7. Furlani BA, Meyer CH, Rodrigues EB, et al. Emerging pharmacotherapies for diabetic macular edema. Expert Opin Emerg Drugs 2007;12:591-603 (Pubitemid 350189125)
8. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538 (Pubitemid 44292310)
9. Lam DS, Chan CK, Mohamed S, et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203 (Pubitemid 46202869)
10. Kim JE, Pollack JS, Miller DG, et al.; Isis Study Group. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008;28:735-740
11. Dehghan MH, Ahmadieh H, Ramezani A, et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17 (Pubitemid 351308679)
12. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007;114:2162-2167 (Pubitemid 350181096)
13. Faghihi H, Taheri A, Farahvash MS, et al. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial. Retina 2008 [Epub ahead of print]
14. Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006;124:643-650
15. Zacks DN, Johnson MW. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina 2005;25:135-140 (Pubitemid 40365935)
16. Margolis R, Singh RP, Bhatnagar P, Kaiser PK. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmol 2008;86:105-110
17. Ip MS, Bressler SB, Antoszyk AN, et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina 2008;28:919-930
18. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449 •• A large, prospective, multicenter randomized clinical trial, done by the Diabetic Retinopathy Clinical Research Network, comparing two doses of intravitreal triamcinolone acetonide to photocoagulation in patients with diabetic macular edema.
19. Beck RW, Edwards AR, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net), Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251
20. Chu YK, Chung EJ, Kwon OW, et al. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye 2007 [Epub ahead of print]
21. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006;141:629-637
22. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003 (Pubitemid 44140181)
23. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743 (Pubitemid 39452920)
24. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198-205
25. Gerzenstein SM, Pletcher MT, Cervino ACL, et al. Glucocorticoid receptor polymorphisms and intraocular pressure response to intravitreal triamcinolone acetonide. Ophthalmic Genet 2008;29:166-170
26. Bhavsar AR, Ip MS, Glassman AR, DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone acetonide injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-456
27. Moshfeghi DM, Kaiser PK, Bakri SJ, et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005;36:24-29 (Pubitemid 40128598)
28. Roth DB, Prenner JL, Krajnyk O. Incidence of noninfectious endophthalmitis after intravitreal injection of preservative-free triamcinolone acetonide. Retin Cases Brief Rep 2008;2:247-249
29. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-3849 (Pubitemid 44264695)
30. Chew E, Strauber S, et al. Diabetic Retinopathy Clinical Research Network, Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007;114:1190-1196
31. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027 (Pubitemid 43795240)
32. Fluocinolone acetonide ophthalmic - Bausch & Lomb: fluocinolone acetonide Envision TD implant. Drugs R D 2005;6:116-119 (Pubitemid 40485256)
33. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317 (Pubitemid 46425557)
34. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434 (Pubitemid 36910021)
35. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489
36. Scott IU, Edwards AR, et al. Diabetic Retinopathy Clinical Research Network, A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:186-187
37. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-1195 (Pubitemid 350211523)
38. Lam DSC, Lai TYY, Lee VYW, et al. Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized clinical trial. Retina 2009;29:292-299
39. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80
40. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861
41. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008;18:263-269 (Pubitemid 351692187)
42. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216 (Pubitemid 351224097)
43. Rosenfeld PR, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431 (Pubitemid 44511557)
44. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444 (Pubitemid 44511558)
45. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712 (Pubitemid 44442451)
46. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-969 (Pubitemid 44853891)
47. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00284050?term= ranibi zumab+resolve&rank;1 [Accessed 19 October 2008]
48. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00687804? term+ranibi zumab&rank+4 [Accessed 19 October 2008]
49. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805- 2816 (Pubitemid 40051904)
50. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757 (Pubitemid 41400011)
51. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-28 (Pubitemid 43021723)
52. Krishnan R, Goverdhan S, Lochhead J. Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye 2008 [Epub ahead of print]
53. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633-642
54. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24(5 Suppl):S3-19 (Pubitemid 39391785)
55. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349 (Pubitemid 44702055)
56. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R D 2008;9:261-269 (Pubitemid 351940898)
57. Do DV, Nguyen QD, Browning DJ, et al. An exploratory study of the safety, tolerability and biological effect of a single intravitreal administration of vascular endothelial growth factor trap-eye in patients with diabetic macular oedema. Br J Ophthalmol 2009;93:144-149 • A Phase I clinical trial of VEGF Trap-Eye in patients with diabetic macular edema.
58. Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-972 (Pubitemid 41358195)
59. Dejneka NS, Wan S, Bond OS, et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis 2008;14:997-1005 (Pubitemid 351803426)
60. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:573-584 (Pubitemid 41455296)
61. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-597
62. Bhavsar A, Grillone L, McNamara T, et al. Predicting response of vitreous hemorrhage and outcome of photocoagulation after intravitreous injection of highly purified ovine hyaluronidase in patients with diabetes. Invest Ophthalmol Vis Sci 2008 [Epub ahead of print]
63. Lopez-Lopez F, Rodriguez-Blanco M, Gomez-Ulla F, Marticorena J. Enzymatic vitreolysis. Curr Diabetes Rev 2009;5:57-62
64. Gandorfer A. Enzymatic vitreous disruption. Eye 2008;22:1273-1277
65. Williams JG, Trese MT, Williams GA, Hartzer MK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology 2001;108:1902-1905 (Pubitemid 32905953)
66. Hirata A, Takano A, Inomata Y, et al. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. Retina 2007;27(8):1074-1078 (Pubitemid 350304010)
67. Azzolini C, D'Angelo A, Maestranzi G, et al. Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol 2004;138:560-566 (Pubitemid 39420482)
68. Sakuma T, Tanaka M, Inoue J, et al. Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur J Ophthalmol 2006;16:138-140
69. Diaz-Llopis M, Udaondo P, Garcia-Delpech S, et al. Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema. Arch Soc Esp Oftalmol 2008;83:77-84
70. Quiram PA, Leverenz VR, Baker RM, et al. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007;27:1090-1096 (Pubitemid 350304013)
71. Available from: http://clinicaltrials.gov/ct2/ show/NCT00798317? term+microplasmin+ vitrectomy&rank=3 [Accessed 16/3/09]
72. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. assessment of anti-inflammatory efficacy. Inflammation 2000;24:357-370 (Pubitemid 30367882)
73. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007;56:373-379 (Pubitemid 46263075)
74. Hariprasad SM, Callanan D, Gainey S, et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther 2007;23:585-590 (Pubitemid 350204684)
75. Ducharme E, Weinberg JM. Etanercept. Expert Opin Biol Ther 2008;8:491-502
76. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, et al. The use of intravitreal etanercept in diabetic macular edema. Semin Ophthalmol 2007;22:75-79 (Pubitemid 46918888)
77. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor á for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035
78. Sfikais PP, Markomichelakis N, Theodossiadis PG, et al. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005;28:445-447 (Pubitemid 40170961)
79. Aiello LP. The potential role of PKC â in diabetic retinopathy and macular edema. Surv Ophthalmol 2002;47(Suppl 2):S263-9 (Pubitemid 36351246)
80. Donnelly R, Idris I, Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004;88:145-151 (Pubitemid 38091382)
81. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188-2197
82. PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-2230
83. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318-324 • A large, multicenter, prospective, randomized clinical trial of ruboxistaurin in patients with diabetic macular edema.
84. Davis MD, Sheetz MJ, Aiello LP, et al. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 2009;50:1-4
85. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007;67:121-153 (Pubitemid 46105094)
86. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-1697 • A large, prospective, multicenter, randomized clinical trial of fenofibrate in patients with diabetic retinopathy. (Pubitemid 350100775)
87. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
88. Zhang J, Mcgwin G Jr. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol 2007;125:1096-1099 (Pubitemid 47258040)
89. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diab Med 2000;17:287-294 (Pubitemid 30266123)
90. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-9121 (Pubitemid 29164719)
91. Shen LQ, Child A, Weber GM, et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 2008;126:793-799 (Pubitemid 351831328)
92. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006;26:562-570 (Pubitemid 44620399)
93. Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev Ophthalmol 2007;39:111-121
94. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000;23:504-509 (Pubitemid 30185795)
95. Boehm BO, Lang GK, Jehle PM, et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001;33:300-306 (Pubitemid 32579247)
96. Kierkegaard C, Norgaard K, Snorgaard O, et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh) 1990;122:766-772 (Pubitemid 20220425)
97. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes - insight from the FIELD study. Curr Pharm Des 2009;15:537-552
98. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278 (Pubitemid 44318179)